{"nctId":"NCT00787891","briefTitle":"A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients","startDateStruct":{"date":"2009-01"},"conditions":["Gastroesophageal Reflux Disease (GERD)"],"count":127,"armGroups":[{"label":"Rabeprazole 0.5 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: rabeprazole"]},{"label":"Rabeprazole 1.0 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: rabeprazole"]}],"interventions":[{"name":"rabeprazole","otherNames":[]},{"name":"rabeprazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of at least 1 Gastroesophageal Reflux Disease (GERD) symptom within 3 months of screening\n* Positive esophagogastroduodenoscopy\n* Signed informed consent\n* Female patients (if menstruating) must be practicing birth control\n\nExclusion Criteria:\n\n* Patients with history of esophagitis\n* Patients who have milk protein allergy\n* Patients who have taken Proton Pump Inhibitors or H2-blockers within 3 days\n* Patients who have taken sucralate or any medication that affects gastrointestinal motility\n* Patients with H. pylori\n* Patients with lab values outside the normal age appropriate range\n* Patients who have participated in another trial within 30 days before screening\n* Patients with allergies to Proton Pump Inhibitors","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Patients With Healing by Week 12 (Short-term Double-blind Treatment Phase)","description":"Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"PRIMARY","title":"The Percentage of Patients With Healing by Week 36 (Double-blind Maintenance Treatment Phase)","description":"Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Short-term Double-blind Treatment Phase)","description":"The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.85"},{"groupId":"OG001","value":"-1.0","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in the Total GERD Symptom and Severity Score (Short-term Double-blind Treatment Phase)","description":"The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.5","spread":"11.70"},{"groupId":"OG001","value":"-8.5","spread":"9.75"}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in the Hetzel and Dent Endoscopic Classification Grade Score (Double-blind Maintenance Treatment Phase)","description":"The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.49"},{"groupId":"OG001","value":"0.2","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"The Change From Baseline in the Total GERD Symptom and Severity Score (Double-blind Maintenance Treatment Phase)","description":"The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"4.82"},{"groupId":"OG001","value":"-1.4","spread":"9.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":65},"commonTop":["Vomiting","Abdominal Pain","Cough","Diarrhoea","Upper Respiratory Tract Infection"]}}}